Natus Medical Incorporated (BABY) Shares Sold by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC reduced its stake in Natus Medical Incorporated (NASDAQ:BABY) by 0.5% during the second quarter, Holdings Channel reports. The firm owned 459,597 shares of the medical equipment provider’s stock after selling 2,449 shares during the period. Rice Hall James & Associates LLC’s holdings in Natus Medical were worth $17,143,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. BlackRock Inc. boosted its position in Natus Medical by 137,510.8% in the first quarter. BlackRock Inc. now owns 4,124,195 shares of the medical equipment provider’s stock valued at $161,874,000 after buying an additional 4,121,198 shares during the period. Vanguard Group Inc. boosted its position in Natus Medical by 4.8% in the first quarter. Vanguard Group Inc. now owns 2,274,870 shares of the medical equipment provider’s stock valued at $89,289,000 after buying an additional 105,008 shares during the period. Columbia Wanger Asset Management LLC boosted its position in Natus Medical by 243.6% in the first quarter. Columbia Wanger Asset Management LLC now owns 2,030,207 shares of the medical equipment provider’s stock valued at $79,686,000 after buying an additional 1,439,382 shares during the period. Wellington Management Group LLP boosted its position in Natus Medical by 105.7% in the first quarter. Wellington Management Group LLP now owns 1,795,094 shares of the medical equipment provider’s stock valued at $70,457,000 after buying an additional 922,268 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in Natus Medical by 2.8% in the first quarter. Dimensional Fund Advisors LP now owns 1,401,566 shares of the medical equipment provider’s stock valued at $55,010,000 after buying an additional 38,125 shares during the period. Institutional investors own 93.86% of the company’s stock.

Natus Medical Incorporated (BABY) opened at 33.55 on Friday. Natus Medical Incorporated has a 12 month low of $32.83 and a 12 month high of $44.39. The firm’s 50-day moving average is $36.43 and its 200-day moving average is $36.70. The company has a market capitalization of $1.09 billion, a PE ratio of 58.15 and a beta of 0.93.

Natus Medical (NASDAQ:BABY) last released its quarterly earnings data on Wednesday, July 26th. The medical equipment provider reported $0.34 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.33 by $0.01. Natus Medical had a return on equity of 12.09% and a net margin of 4.20%. The business had revenue of $122.20 million for the quarter, compared to the consensus estimate of $121.99 million. During the same quarter in the previous year, the company posted $0.39 EPS. The company’s revenue was up 27.3% compared to the same quarter last year. Equities analysts anticipate that Natus Medical Incorporated will post $1.70 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://stocknewstimes.com/2017/08/12/natus-medical-incorporated-baby-shares-sold-by-rice-hall-james-associates-llc.html.

BABY has been the topic of several research analyst reports. Zacks Investment Research cut shares of Natus Medical from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. TheStreet cut shares of Natus Medical from a “b” rating to a “c+” rating in a research report on Thursday, April 27th. BidaskClub upgraded shares of Natus Medical from a “sell” rating to a “hold” rating in a research report on Saturday, July 1st. Finally, Benchmark Co. reiterated a “buy” rating and set a $48.00 price target (down from $55.00) on shares of Natus Medical in a research report on Monday, May 1st. Three analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $45.00.

In related news, insider James B. Hawkins bought 6,000 shares of the business’s stock in a transaction dated Wednesday, May 31st. The shares were purchased at an average price of $33.81 per share, with a total value of $202,860.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider James B. Hawkins bought 4,000 shares of the business’s stock in a transaction dated Thursday, June 15th. The shares were bought at an average cost of $33.98 per share, for a total transaction of $135,920.00. Following the transaction, the insider now owns 578,023 shares in the company, valued at approximately $19,641,221.54. The disclosure for this purchase can be found here. Insiders own 5.50% of the company’s stock.

About Natus Medical

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Want to see what other hedge funds are holding BABY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natus Medical Incorporated (NASDAQ:BABY).

Institutional Ownership by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply